Efficacy of Sacral Erector Spinae Plane Block (SESPB) on Postoperative Pain and Catheter-related Bladder Discomfort
SESPB
Comparison of the Efficacy of Sacral Erector Spinae Plane Block (SESPB) and Pudendal Block on Postoperative Pain and Catheter-related Bladder Discomfort (CRBD) in Patients Undergoing Trans-urethral Resection of the Prostate (TUR-P).
1 other identifier
interventional
54
1 country
1
Brief Summary
The goal of this clinical trial is to evaluate the catheter related bladder discomfort in patients who will undergoing TUR-P operation. The main questions it aims to answer are:
- Is sacral ESPB effective on the pudendal nerve dermatome?
- Is sacral ESPB as useful as pudendal block on CRBD? Participants will be divided into two groups and the first group will receive sacral espb after TUR-p operation and the second group will receive pudendal block. Investigators will be present for 24 hours
- catheter related bladder discomfort
- post-operative pain,
- additional analgesic needs will be questioned and the difference between the two groups will be evaluated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Nov 2023
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 7, 2023
CompletedStudy Start
First participant enrolled
November 12, 2023
CompletedFirst Posted
Study publicly available on registry
November 13, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 15, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 15, 2023
CompletedMay 17, 2024
May 1, 2024
1 month
November 7, 2023
May 15, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Catheter related bladder discomfort, 0:no discomfort 4:worst discomfort
It was evaluated with a 4-point scoring system developed and first used by Agarwall et al. . No symptoms: 0, Mild: mild discomfort that can be tolerated, Moderate: discomfort is present but not accompanied by behavioural reactions, Severe: discomfort is very severe and accompanied by body movements indicating that the patient cannot bear it.
baseline ,and 24 hours
Secondary Outcomes (1)
Numerical Rating Scale,0 :no pain 10:worst pain
baseline, and 24 hours
Study Arms (2)
espb group
EXPERIMENTALBlock will be performed with median technique at the level of sacral 2nd vertebrae.
pudendal group
ACTIVE COMPARATORBilateral transperineal block will be performed
Interventions
Eligibility Criteria
You may qualify if:
- \- American Society of Anesthesiologist (ASA) Physical status 1-3
You may not qualify if:
- American Society of Anesthesiologist (ASA) Physical status 4-5
- Refused to participate in the study
- Known allergy to local anaesthetic
- Where regional anaesthesia is contraindicated
- With known neurological, haematological or muscular disease
- Patients with infection or anatomical changes in the lumbo-sacral region
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Giresun Research and Training Hospital
Merkez, Giresun, 28100, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bilge Olgun Keleş
Giresun University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
November 7, 2023
First Posted
November 13, 2023
Study Start
November 12, 2023
Primary Completion
December 15, 2023
Study Completion
December 15, 2023
Last Updated
May 17, 2024
Record last verified: 2024-05